BioMimetic Therapeutics, Inc.
BioMimetic (NASDAQ: BMTI) is a biotechnology company developing orthopedic surgical devices that deliver purified recombinant human platelet-derived growth factor (rhPDGF-BB) to promote tissue healing and regeneration. rhPDGF-BB is a synthetic form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration. The mechanism of action of PDGF suggests it may be effective in a broad array of musculoskeletal applications, including the repair of bone, ligament, tendon and cartilage. Through the commercialization of this technology, BioMimetic seeks to become the leading company in the field of orthopedic regenerative medicine.
While on staff at Harvard beginning in the mid 1980s, Dr. Samuel Lynch, BioMimetic's president, CEO and founder, conducted research on the role of PDGF in tissue repair and regeneration. These efforts generated a foundation of scientific knowledge and intellectual property from which BioMimetic Therapeutics is now based.
Contact Details
Office Address
BioMimetic Therapeutics, Inc.
389-A Nichol Mill Ln.
Franklin, TN, USA 37067
Phone: (615) 844-1280
Fax: (615) 844-1281
Executives
Chairman
Larry W. Papasan
President, CEO, and Director
Samuel E. Lynch